



**FOR IMMEDIATE RELEASE**

## **Steven Holtzman Joins Compugen as Strategic Business Advisor**

Holon, Israel – May 10, 2016 – Compugen Ltd. ([NASDAQ: CGEN](#)), a leading predictive drug discovery company, announced today that Steven Holtzman, former Executive Vice President, Corporate Development of Biogen, has joined Compugen as a strategic business advisor to the Company.

Anat Cohen-Dayag, PhD, Compugen’s President and Chief Executive Officer, stated, “We are excited to welcome Steven Holtzman, as a strategic business advisor to the Company. Steve brings a remarkable breadth of experience on multiple business fronts of the biotech industry, in which he led numerous successful business transactions. At Biogen, he created and led its Program Leadership and Management Group through its prosecution of five new drug approvals as well as its Business Development and M&A group in numerous transactions. We look forward to working with Steve and benefiting from his guidance and experience as we advance toward our goal of transforming novel immuno-oncology targets into the next wave of cancer immunotherapies.”

Mr. Holtzman has been a leading entrepreneur and executive in the biotechnology field since the mid-1980’s. Most recently he was the Executive Vice President, Corporate Development of Biogen. Previously, he served as the founder, CEO and Chairman of the Board of Directors of Infinity Pharmaceuticals, Inc., and the Chief Business Officer of Millennium Pharmaceuticals, Inc. In addition, Mr. Holtzman was a founder, member of the Board and the Executive Vice President of DNX Corporation. Currently, he is a member of the boards of directors of PMV Pharma, Visterra and Molecular Partners. In the not-for-profit arena, Mr. Holtzman is a Trustee of the Berklee College of Music, and previously served as the Vice Chairman of the Board of Trustees of the Hastings Center for Ethics and the Life Sciences and as a Presidential appointee to the US National Bioethics Advisory Commission. He received his B.A. in Philosophy from Michigan State University and his B.Phil. graduate degree in Philosophy from Corpus Christi College, Oxford University, which he attended as a Rhodes Scholar.

### **About Compugen**

Compugen is a leading therapeutic discovery company utilizing its broadly applicable predictive discovery infrastructure to identify novel drug targets and develop first-in-class biologics. The primary focus of the Company’s current pipeline is on immune checkpoint target candidates discovered by the Company, potentially providing the basis for a next wave of therapeutics for cancer immunotherapy. Compugen’s business model is based on selectively entering into

collaborations for its novel target candidates and drug product candidates at various stages of research and development under revenue-sharing agreements. The Company is headquartered in Israel, with R&D facilities in Israel and South San Francisco. At the US facilities, monoclonal antibody therapeutic candidates are discovered and developed against the Company's novel target candidates. For additional information, please visit Compugen's corporate website at <http://www.cgen.com>.

### **Forward-Looking Statement**

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of terminology such as "will," "may," "expects," "anticipates," "believes," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Among these risks: Compugen's business model is substantially dependent on entering into collaboration agreements with third parties and may not be successful in generating adequate revenues or commercializing aspects of our business model, and the development and commercialization of therapeutic candidates involve many inherent risks, including failure to progress to clinical trials or, if they progress to or enter clinical trials, failure to receive regulatory approval. These and other factors are more fully discussed in the "Risk Factors" section of Compugen's most recent Annual Report on Form 20-F as filed with the Securities and Exchange Commission as well as other documents that may be subsequently filed by Compugen from time to time with the Securities and Exchange Commission. In addition, any forward-looking statements represent Compugen's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Compugen does not assume any obligation to update any forward-looking statements unless required by law.

### **Company contact:**

Tsipi Haitovsky  
Global Media Liaison  
Compugen Ltd.  
Email: [tsipih@cgen.com](mailto:tsipih@cgen.com)  
Tel: +972-52-598-9892